Transplantation of Cryopreserved Fetal Liver Hemopoietic Cells in Complex Treatment of Cancer Patients
A.I. Smikodub. Yu.A. Grinevich, G.D. Bendyug, L.V. Radziyevskaya, V.V. Snigir, N.N. Khranovskaya, I.Yu. Glukhovskaya, V.S. Ivankova
Information concerning the ability of the transplanted fetal liver hemopoietic cells (FLHC) to restore hemopoiesis and immune system, as well as our former experimental investigations that had shown the FLHC ability to hamper metastasizing in experimental animals, gave us the ground to elaborate the scheme for complex treatment of the patients with solid tumors, which includes FLHC transplantation.
32 patients with depression of hemopoiesis and immune system were treated: 16 children from 2 to 15 years old (13 with osteogenic sarcoma, 3 with Wilms tumor) and 16 women with cervical cancer from 21 to 60 years old. Transplanted were cryopreserved FLHC of 7 to 12 weeks of gestation. The volume of suspension transplanted was 2–4 ml with cells contents at 0.1–4.0 x 108
and CFU-GEMM contents at 0.5-9.0x103
We ascertained that the use of FLHC transplantation while treating oncology patients inhibits cytopenia progression and improves the immune state and relative indices, with corresponding melioration of patients' general state. The effects observed prove that the complex treatment including the FLHC transplantation of the patients with the solid tumors is much more effective.
Rezultat tretmana fetalnim matičnim ćelijama zavisi od: težine bolesti, starosne dobi pacijenta, doslednosti i privrženosti medikaciji i režimu. Rezultati tretmana, prezentovani na ovom sajtu, su individualni za svaki klinički slučaj.